A Network Built for Patients - GeneDx in 2026

A message from Katherine Stueland, President & CEO

Everything we do at GeneDx is grounded in one simple truth: an accurate genetic diagnosis changes everything. It changes the trajectory of a patient's life. It changes how clinicians act in the moments that matter most. And it changes what becomes possible for medicine. It's how we deliver on our mission – empowering everyone to live their healthiest life through genomics.

For too long, the experience of rare disease has been defined by uncertainty and delay. Millions of families are still navigating diagnostic odysseys that last years – sometimes decades – searching not only for a diagnosis, but for clarity, direction, and hope. GeneDx exists to end that wait. We believe no family should have to endure years of uncertainty when answers can arrive in days, or even hours.

When I became CEO, I saw a rare opportunity: to scale a genomics engine powerful enough to reshape care for the youngest patients today and improve health for millions more in the years ahead. That belief – that we can build a company that grows *because* we help families faster – guides everything we do. A strong, disciplined, and profitable GeneDx is not the goal itself; it's the vehicle that lets us reach more families, earlier, with answers that truly change lives.

As we enter 2026, GeneDx is accelerating. We are expanding – scaling across care settings, growing internationally, deepening partnerships across the healthcare ecosystem, and investing in the data and expertise that will define the next era of precision medicine – to make earlier diagnosis the norm, not the exception. Our growth is purposeful, and it is inseparable from our impact.

Reaching More Families Faster

Last year's American Academy of Pediatrics recommendation for first-line genomic testing is more than a milestone – it's a tipping point. It signaled a broader shift in medicine – from "wait and see" – to "test early, act early." That shift aligns squarely with what we have long known: the earlier a family receives an answer, the better the outcome.

Every step earlier in the care pathway creates exponential value. In prenatal care, genomic clarity helps families and clinicians navigate complex decisions before birth. In the NICU and PICU, rapid exome and genome sequencing can change outcomes in hours, not months. Genomic newborn screening enables truly preventive care by identifying disease

before symptoms appear. In primary care pediatrics, genomics is becoming a frontline tool, bringing answers to millions of children at the very start of their journey. And for adults, genomic testing is finally unlocking answers for people who have waited far too long.

Pediatricians are at the center of this transformation. Our role is to make genomics easy to access, easy to trust, and easy to integrate into everyday care – with accurate diagnosis as the central, unifying force of the rare-disease network. We are redesigning workflows, simplifying ordering and results delivery, and surrounding clinicians with GeneDx experts as an extension of their teams. This evolution improves outcomes for patients while driving durable, sustainable growth for our business.

Globally, our interpretation platform extends GeneDx expertise into health systems around the world. Through flexible models, including interpretation-as-a-service, we are able to meet local needs while strengthening the shared learning of a global network. Wherever sequencing occurs, GeneDx helps ensure families benefit from the highest standard of genomic science.

A Data Foundation Built from Real Patients

At the heart of this network is GeneDx Infinity™ – the world's largest genomic rare disease dataset – built from real patients over more than two decades. In 2025 alone, we generated 30% more exome and genome data than in the previous 24 years combined. Today, Infinity represents more than two million patients, nearly one million sequenced exomes and genomes, and is the central intelligence layer for rare disease diagnosis.

Through our partnership with Komodo Health, we are connecting genomic insight with longitudinal clinical outcomes, creating the most comprehensive view yet of how rare diseases are diagnosed, managed, and treated over time. This growing body of knowledge benefits patients first. With every diagnosis, the system becomes stronger. Each patient contributes to faster, more precise diagnoses for the next.

But size alone doesn't create value – *insight leading to action does*.

This is why we're building a network at the center of rare disease – a living, learning system that connects patients, clinicians, health systems, researchers, biopharma partners, policymakers, and advocates – into one precision-medicine ecosystem. And when that system works the way it should, diagnosis is no longer the end of the story. It becomes the beginning of a future.

It also accelerates discovery across the healthcare ecosystem – from research to biopharma to the development of future therapies. With the vast majority of rare diseases

still lacking an approved treatment, this work represents a profound opportunity to change what is possible. With the largest, most comprehensive and longitudinal rare disease dataset, we are closer to a future where patients get answers – and access to effective therapies – faster than ever before.

Infinity is our enduring advantage. Technology and AI amplify every opportunity – enabling faster diagnoses, greater precision, and seamless clinical workflows – so families and clinicians get answers with less friction, less delay, and far more confidence. Together, these strengths put diagnosis at the center of a connected ecosystem built to serve families first and compound impact for decades. It's why GeneDx can lead not only in diagnostics today, but in shaping the future of precision genomic medicine.

Growth With Purpose

Our growth is tangible and grounded in service to families. In 2025, we delivered strong performance across revenue, volume, and margins, with more details available here.

The only way we grow is by serving more families and serving them earlier. Our growth engines – pediatric specialists, pediatricians, NICU, prenatal, adult, genomic newborn screening, international expansion, and biopharma discovery – all scale when we reduce time-to-answer and increase time-to-impact. Profitability allows us to reinvest in what matters most: innovation, clinical excellence, and the ability to reach more families with answers and next steps.

That momentum continues into 2026, with expectations for sustained growth, expanding reach, and continued profitability.

Growth is our mission at work.

Building on a 25-Year Legacy

Over 25 years, GeneDx diagnosed more than 4,800 genetic diseases, contributed to over 500 gene discoveries, and published more than 1,000 peer-reviewed studies. That foundation has earned the trust of clinicians and made GeneDx the most widely used genetic test for children today.

But what matters most is what this legacy enables now and what comes next.

As we enter 2026, GeneDx is profitable, accelerating, and poised to make early diagnosis the standard of care for every child, everywhere. Behind every strategy and every dataset is a real family: a parent searching for clarity, a newborn fighting for survival, an adult finally receiving an answer after years of uncertainty.

We are building a company that ensures families never have to wait.

Helping more families get answers sooner – and healthier faster – that's our growth story. And we're only just beginning.

Forward-looking statements: Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our press release dated January 12, 2026 for a discussion of factors that could cause actual results to materially differ from forward-looking statements.